Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nkarta, Inc. - Common Stock (NQ:NKTX)

1.620 -0.080 (-4.71%)
Streaming Delayed Price Updated: 12:07 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nkarta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
The Latest Analyst Ratings for Nkarta
Via Benzinga
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
These Biotech Stocks Could Double Your Money, According To Analysts
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
Via Benzinga
Analyst Expectations for Nkarta's Future
Via Benzinga
Visa To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
The Latest Analyst Ratings for Nkarta
Via Benzinga
Analyst Expectations for Nkarta's Future
Via Benzinga
What's Going With Cancer-Focused Nkarta Stock Today?
Nkarta Inc (NASDAQ: NKTX) received FDA clearance for its Investigational New Drug (IND) application to evaluate NKX019, its allogeneic, CD19-directed CAR NK cell therapy candidate,  
Via Benzinga
Exposures Product Safety
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
From Nkarta, Inc.
Via GlobeNewswire
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
Call scheduled for Tuesday, October 17, 2023 at 8:00 a.m. ET 
From Nkarta, Inc.
Via GlobeNewswire
3 Promising Biotech Stocks That Will Make Early Investors Rich
Despite their volatility, certain biotech stocks stand out for their innovative approaches and potential game-changing therapies. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 112 companies set new 52-week lows. 
Via Benzinga
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
3 Hidden Penny Stocks That Could Turn $100 into $10,000
These penny stocks have multibagger upside potential with great margins of safety, according to Wall Street analysts. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 283 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday's session saw 43 companies set new 52-week lows. 
Via Benzinga
NKX101's Leukemia Setting Phase 1 Results a Setback for Nkarta: Analyst Lowers Price Target Amid Revised Development Timeline
Nkarta Inc (NASDAQ: NKTX) announced updated data from the Phase 1 study of NKX101 to treat patients with relapsed or refractory (r/r)  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. 
Via Benzinga
Nkarta's Updated Data From Leukemia Study Fails To Cheer Investors
Nkarta Inc (NASDAQ: NKTX) announced updated data from the Phase 1 study of NKX101 to treat patients with relapsed or refractory (r/r)  
Via Benzinga
Why Shares of Nkarta Are Slumping Tuesday
The pharmaceutical stock dropped after announcing so-so clinical trial results. 
Via The Motley Fool
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
From Nkarta, Inc.
Via GlobeNewswire
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
Call scheduled for Tuesday, June 27, 2023 at 8:00 a.m. ET 
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
7 Stocks With Promising Upside Potential for 100% Returns
If you still want to gamble even during this market environment, these are the stocks with 100% upside potential. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.